Is Inhaled Insulin Delivery Still A Possibility? Why Has It Been A Commercial Failure?

The commercial failure of Exubera, the first inhaled insulin product to come to market, led other companies such as Eli Lilly-Alkermes to halt studies of similar drug delivery in development intended to compete for a share of the lucrative diabetes market. Does this signal defeat for efforts to deliver insulin via the lungs?

Read the whole article on Science Daily

More from Science Daily